Behavioural toxicity of medicinal drugs: Practical consequences, incidence, management and avoidance

Drug Safety

Volumn 18, Issue 3, 1998, Pages 189-208

  Ramaekers, Johannes G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANXIOLYTIC AGENT; BELLADONNA ALKALOID; BENZODIAZEPINE; DIAZEPAM; FLURAZEPAM; HYPNOTIC AGENT; INSULIN; LORAZEPAM; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXAZEPAM; PICROTOXIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VASODILATOR AGENT;

ACCIDENT; AGGRESSION; BEHAVIOR DISORDER; BEHAVIOR MODIFICATION; COGNITION; DAILY LIFE ACTIVITY; DRIVING ABILITY; DROWSINESS; DRUG INFORMATION; DRUG TOXICITY; DRUG USE; FALLING; HUMAN; INJURY; INSOMNIA; LETHARGY; MOTIVATION; OCCUPATIONAL ACCIDENT; PARANOIA; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOSOCIAL WITHDRAWAL; REVIEW; TASK PERFORMANCE;

ACCIDENTAL FALLS; ACCIDENTS, OCCUPATIONAL; ACCIDENTS, TRAFFIC; BEHAVIOR; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0031890844     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818030-00004     Document Type: Review

References (177)

1. Snyder SH. Madness and the brain. New York: McGraw-Hill, 1975
2. Jaffe JH. Drug addiction and drug abuse. In: Goodman Gilman A, Wall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 522-73.
3. Linnoila M, Guthrie S, Lister R. Mechanisms of drug-induced impairment of driving. In: O'Hanlon JF, De Gier H, edilors. Drugs and driving. London: Taylor and Francis, 1986: 29-50
4. Cole JO. Behavioral toxicity. In: Uhr L, Miller JG, editors. Drugs and behavior. New York: John Wiley & Sons 1960: 375
5. Fingl E, Woodbury DM. General principles. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 3rd ed. New York: MacMillan, 1964: 1
6. Dimascio A, Shader RI. Behavioral toxicity of psychotropic drugs: I. Definition. II. Toxic effects on psychomotor functions. Conn Med 1968; 32: 617-20
7. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995; 5: 239-44
8. Neutel CI, Downey W, Senft D. Medical events after a prescription for a benzodiazepine. Pharmacoepidemiol Drug Saf 1995; 4: 63-73
9. Ray WA, Griffin MR, Schaffner W, et al. Psychopytropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-9
10. Granek E, Baker SP, Abbey H, et al. Medications and diagnoses in relation to falls in a long-term care facility. J Am Geriatr Soc 1987; 35: 503-11
11. Ray WA, Griffin MR, Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991; 151: 754-6
12. Ryynänen OP, Kivelä SL, Honkanen R, et al. Medications and chronic diseases as risk factors for falling injuries in the elderly. Scand J Soc Med 1993; 21: 264-71
13. Lichtenstein ML, Griffin MR, Cornell JE, et al. Risk factors for hip fractures occurring in the hospital. Am J Epidemiol 1994; 140: 830-8
14. Cumming RG, Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993; 158: 414-7
15. Shorr RI, Griffin MR, Daugherty JR, et al. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propovyphene. J Gerontol 1991; 47: 111-5
16. Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5: 591-8
17. Koepsell TD, Wolf ME, McClosky L, et al. Medical conditions and motor vehicle collision injuries in older adults. J Am Geriatr Soc 1994; 42: 695-700
18. Gilmore TM, Alexander BH, Mueller BA, et al. Occupational injuries and medication use. Am J Ind Med 1996; 39: 234-9
19. Cumming RG, Miller JP, Kelsey JL, et al. Medications and multiple falls in elderly people: The St Louis OASIS study. Age Ageing 1991; 20: 455-461
20. Govaarts JJGM, Nooren FPBM, Smeekens PFJ, et al. Benzodiazepines en bedrijfsongevallen. Tijdschr Sociale Gezondheidswetenschappen 1989; 67: 131-3
21. Malmivaara A, Heliövaara M, Knekt P, et al. Risk factors for injurious falls leading to hospitalization or death in a Cohort of 19500 adults. Am J Epidemiol 1993; 138: 384-94
22. Lord SR, Anstey KJ, Williams P, et al. Psychoactive medication use, sensori-motor function and falls in older women. Br J Clin Pharmacol 1995; 39: 227-34
23. Ruthazer R, Lewis AL. Antidepressants and falls among elderly people in long-term care. Am J Public Health 1993; 83: 746-9
24. Maxwell CJ, Neutel I, Hirdes JP. A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiol Drug Saf 1997; 6: 27-35
25. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136: 873-83
26. Oster G, Russel MW, Huse DM, et al. Accident- and injury-related health care utilization among benzodiazepine users and nonusers. J Clin Psychiatry 1987; 48 Suppl.: 17-21
27. Oster G, Huse DM, Adams SF, et al. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 1990; 80: 1467-70
28. Currie D, Hashemi K, Fothergill J, et al. The use of anti-depressants and benzodiazepines in the perpetrators and victims of accidents. Occup Med 1995; 45: 323-5
29. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly living in the community. N Engl J Med 1988; 319: 1701-7
30. Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly people at home: Prevalence and associated factors. Age Aging 1988; 17: 365-72
31. Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in a community-based prospective study of people 70 years and older. J Gerontol 1989; 44: M112-117
32. Campbell AJ, Borrie MJ, Spears GF, et al. Circumstances and consequences of falls experienced by a community population 70 years and over during a prospective study. Age Aging 1990; 19: 136-41
33. Cwikel J. Falls among elderly people living at home: medical and social factors in a national sample. Isr J Med Sci 1992; 28: 446-53
34. Sheahan SL, Coons SJ, Robbins CA, et al. Psychoactive medication, alcohol use, and falls among older adults. J Behav Med 1995; 18: 127-39
35. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-1994. Allergy 1995; 50: 234-42
36. Van Laar MW, Volkerts ER, Van Willigenburg APP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12: 86-95
37. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. Neuropsychobiology 1995; 31: 81-8
38. Ramaekers JG, Ansseau M, Muntjewerff ND, et al. Considering the P450 cytochrome system as determining the effects of antidepressants and benzodiazepines on the actual driving performance of outpatients suffering from major depression. Int Clin Psychopharmacol 1997; 12: 159-69
39. Freeman HL, O'Hanlon JF. Acute and subacute effects of antidepressants on performance. J Drug Dev Clin Pract 1995; 7: 7-20
40. Saletu B, Pekesch G. Recent advances in clinical pharmacology of benzodiazepines part II: pharmacodynamics. Hum Psychopharmacol 1987; 2: 61-84
41. Koelega HS. Benzodiazepines and vigilance performance: a review. Psychopharmacology 1989; 98: 145-56
42. Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992; 44; 151-347
43. O'Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982; 217: 79-81
44. O'Hanlon JF, Brookhuis KA, Louwerens JW, et al. Performance testing as part of drug registration. In: JF O'Hanlon, JJ De Gier, editors. Drugs and driving. London: Taylor and Francis, 1986: 311-30
45. O'Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18: 121s-9s
46. O'Hanlon JF, Volkerts ER. Hypnotics and actual driving performance. Acta Psychiatr Scand 1986; 332: s95-104
47. Volkerts ER, O Hanlon JF. Hypnotics' residual effects on driving performance as determined by drug, dosage, time after administration and nights of continual use. In: JF O'Hanlon, JJ De Gier, editors. Drugs and driving. London: Taylor and Francis, 1986: 123-36
48. Brookhuis KA, Borgman AE:. The effects of some anxiolytics on driving performance. TGO Tijdschrift Therapie Geneesmiddel Onderzoek 1988; 13: 228-31
49. Volkerts ER, Abbink F, van Laar MW, et al. Comparison of the effects of ritanserin 5 mg bid and lorazepam 1 mg tid upon actual driving performance. Technical report. Utrecht. The Netherlands Institute for Drugs and Doping Research, University of Utrecht, 1991
50. Volkerts ER, Van Laar MW, Van Willigenburg APP, et al. A comparative study of on the road and simulated driving performance after nocturnal treatment wilh lormetazepam 1mg and oxazepam 50mg. Hum Psychopharmacol 1992; 7: 297-310
51. O'Hanlon JF. Review of buspirone's effects on human performance and related variables. Eur Neuropsycholopharmacol 1991; 1: 489-501
52. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992; 43: 597-601
53. Balkin TJ, O'Donnell, Wesensten N, et al. Comparison of the daytime sleep and performance effects of zolpidem versus triazolam. Psychopharmacology 1992; 107: 83-8
54. Allain H, Patat A, Lieury A, et al. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics. Eur Psychiatry 1995; 10: 129s-36s
55. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hynotics. Psychopharmacology 1994; 116: 130-4
56. Vermeeren A, O'Hanlon JF, Declerck AC, et al. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995; 21: 47-64
57. Patat A, Perault MC, Vandel B, et al. Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers. J Psychopharmacol 1995; 9: 91-101
58. O'Hanlon JF, Volkerts ER, Louwerens JW, et al. Zopiclone's residual effects on actual driving performance versus those of nitrazepam and flunitrazepam. Clinical Neuropharmacology 1984; 7: 620s-1s
59. O'Hanlon JF. Zopiclone's residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: a critical review. European Psychiatry 1995; 10; 137s-44s
60. Curran HV. Tranquillizing memories: a review of the effects of benzodiazepines on human performance. Biol Psychol 1986; 23: 179-213
61. Kirk T, Roache JD, Griffiths RR. Dose response evaluations of the amnestic effects of triazolam and pentobarbital in normal subjects. J Clin Psychopharmacol 1990; 10: 160-7
62. Dershwitz M, Rosow CE, Dibiase PM, et al. Comparison of the sedative effects of butorphanol and midazolam. Anesthesiology 1991; 74: 717-24
63. Curran HV, Shifano F, Lader M. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology 1991; 103: 83-90
64. Curran HV, Birch B. Differentiating the sedative, psychomotor and amnestic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil. Psychopharmacology 1991; 103: 519-23
65. Hommer H, Weingarter H, Breier A. Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pretreatment. Psychopharmacology 1993; 112: 455-60
66. Pomara N, Deptula D, Medel M, et al. Effects of diazepam on recall memory: relationship to aging, dose, and duration of treatment. Psychopharmacol Bull 1989; 25: 144-8
67. Gorenstein C, Bernik MA, Pompeia S. Differential acute psychomotor and cognitive effects on diazepam on long-term benzodiazepine users. Int Clin Psychopharmacol 1994; 9: 145-53
68. Danion JM, Zimmerman MA, Willard-Schroeder D, et al. Diazepam induces a dissociation between explicit and implicit memory. Psychopharmacology 1989; 99: 238-43
69. Weingarter HJ, Hommer D, Lister RG, et al. Selective effects of triazolam on memory. Psychopharmacology 1992; 106: 341-5
70. Curran HV, Gorenstein G. Differential effects of lorazepam and oxazepam on priming. Int Clin Psychopharmacol 1993; 8: 37-42
71. Polster MR, McCarthy RA, O'Sullivan G, et al. Midazolam induced amnesia: implications for the implicit/explicit memory distinction. Brain Cogn 1993; 22: 244-65
72. Bishop KI, Curran HV, Lader M. Do scopolamine and lorazepam have dissociable effects on human memory systems? A dose response study with normal volunteers. Exp Clin Psychopharmacol 1996; 4: 292-9
73. Starr JM, Whalley LJ. Drug-induced dementia. Incidence, management and prevention. Drug Saf 1994; 11: 310-7
74. Cole JO, Kando JC. Adverse behavioral events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993; 54: s49-61
75. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996; 16: s1-9
76. 1 receptor antagonists. Comparative tolerability and safety. Drug Saf 1994; 10: 350-80
77. Coccaro EF, Siever LJ. Second generation antidepressants: a comparative review. J Clin Pharmacol 1985; 25: 241-60
78. Deptula D, Pomara N. Effects of antidepressants on human performance: a review. J Clin Psychopharmacol 1990; 10: 105-10
79. Tompson PJ. Antidepressants and memory: a review. Hum Psychopharmacol 1991; 6: 79-90
80. Riedel WJ, Van Praag HM. Avoiding and managing anticholinergic effects of antidepressants. CNS Drugs 1995; 3: 245-59
81. Hobi V, Gastpar M, Gastpar G, et al. Driving ability of depressed patients under antidepressants. J Int Med Res 1982; 10: 65-81
82. Siegfried K, O'Connoly M. Cognitive and psychomotor effects of different antidepressants in the treatment of old age depression. Int Clin Psychopharmacol 1986; 1: 231-43
83. Moon CAL, Davey A. The efficacy and residual effects of trazodone (150 mg nocte) and mianserin in the treatment of depressed general practice patients. Psychopharmacology 1988; 95: s7-13
84. Peselow ED, Corwin J, Fieve RR, et al. Disappearance of memory deficits in outpatient depressives responding to imipramine. J Affect Disord 1991; 21: 173-83
85. Austin MP, Ross M, Murray C, et al. Cognitive function in major depression. J Affect Disord 1992; 25: 21-30
86. Robbe HWJ, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995; 5: 35-42
87. Ramaekers JG, Van Veggel LMA, O'Hanlon JF. A cross-study comparison of the effects of moclobemide and brofaromine on actual driving performance and estimated sleep. Clin Neuropsychopharmacol 1994; 17: s9-18
88. Curran HV, Lader M. The pharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol 1986; 29: 601-7
89. Seppälä T, Linnoila M, Elonen E, et al. Effects of tricyclic antidepressants and alcohol on psychomotor skills related to driving. Clin Pharmacol Ther 1975; 17: 515-21
90. Dijen JB, Loriaux SM, Orlebeke JF, et al. Effects of paroxetine and maprotiline on mood, perceptual-motor skills and eye movements in healthy volunteers. J Psychopharmacol 1989; 3: 149-55
91. Stromberg O, Sepällä T, Mattila MJ. Acute effects of maprotiline, doxepin and zimeldine with alcohol in healthy volunteers. Arch Pharmacodynamics Ther 1988; 291: 217-28
92. Moon CAL, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pharmacol 1991; 45: 259-62
93. Ramaekers JG, Swijgman HF, O'Hanlon JF. Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology 1992; 106: s62-7
94. Ramaekers JG, Muntjewerff, O'Hanlon JF. Acute and subchronic effects of mirtazapine (15/30mg nocte) and mianserin (30/60mg nocte) on psychomotor and actual driving performance and sleep in healthy, young volunteers [abstract]. Eur Neuropsychopharmacol 1995; 5: 294
95. Hindmarch I, Shillingford J, Shillingford C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990; 12: s34-6
96. Fairweather DB, Kerr KS, Harrison DA, et al. A double blind comparison of fluoxetine and amitriptyline on cognitive function in elderly depressed patients. Hum Psychopharmacol 1993; 8: 41-7
97. Hale AS, Pinninti NR. Critical flicker fusion threshold and anticholinergic effects of chronic antidepressant treatment in remitted depressives. J Psychopharmacol 1995; 9: 258-66
98. Sakulsripong M, Curran HV, Lader M. Does tolerance develop to the sedative and amnestic effects of antidepressants? Eur J Clin Pharmacol 1991; 40: 43-8
99. Spring B, Gelenberg AJ, Garvin R, et al. Amitriptyline, clovoxamine and cognitive function: a placebo controlled comparison in depressed out-patients. Psychopharmacology 1992; 108: 327-3
100. Ramaekers JG, Muntjewerff ND, Uiterwijk MMC, et al. A study of the pharmacodynamic interaction between befloxatone and ethanol on performance and mood in healthy volunteers. J Psychopharmacol 1996; 10: 288-94
101. Patat A, Gandon JM, Durrieu G, et al. Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxalone, on psychomotor performance and memory in healthy subjects. Hum Psychopharmacol 1995; 19: 111-25
102. Hindmarch I, Kerr JS. Behavioral toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology 1992; 106: s49-55
103. Allain H, Lieury A, Brunet-Bourgin F, et al. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1992; 106: s56-61
104. Fairweather DB, Kerr JS, Hindmarch I. The effects of moclobemide on psychomotor performance and cognitive function. Int Clin Pharmacol 1993; 8: 43-7
105. Herberg KW, Menke H. Study of the effects of the antidepressant fluvoxamine on driving skills and its interaction with alcohol. TÜV Rheinland (Cologne) Technical Report, Cologne, 1981
106. Hindmarch I, Harrison C. The effects of paroxetine and other antidepressants in combination with alcohol in psychomotor activity related to car driving. Human Psychopharmacology 1998; 8: 417-22
107. Kerr JS, Fairweather DB, Mahendran R, et al. The effects of paroxetine alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Pharmacol 1992; 7: 101-8
108. Weinstein A, Wilson S, Bailey S, et al. Sedative antidepressants impair visual detection mechanisms in humans. J Psychopharmacol 1996; 10: 141-5
109. Hindmarch I. A review of the psychomotor effects of paroxetine. International Clinical Psychopharmacology 1992; 6: s65-7
110. Frewer LJ, Lader M. The effects of nefazodone, imipramine and placebo and combined with alcohol, in normal subjects. Int Clin Psychopharmacol 1993; 8: 13-20
111. Van Laar MW, Van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995; 15: 30-40
112. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Psychopharmacol 1995; 39: 397-404
113. O'Hanlon JF, Robbe HWJ, Vermeeren A, et al. Venlafaxine's effects on healthy volunteers' driving, psychomotor and vigilance performance during 15-day fixed (75mg/d) and incremental (75-150mg/d) dosing regimens. Technical report. Maastricht: Institute for Human Psychopharmacology, 1997
114. Farid NA, Bergström RF, Lemberger L, et al. Studies on the disposition of fluoxetine and radioactive isotopes [poster]. 15th Collegium International Neuropsychopharmacologicum; 1986 14-17 Dec; Puerto Rico
115. Newhouse PA, Richter EM. Comparison of sertraline and fluoxetine in depressed geriatric outpatients: plasma levels and efficacy [abstract]. European Neuropsychopharmacol 1996; 6 Suppl. 3: 35
116. Beasley CM, Sayler ME, Bosomworth JC, et al. High dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 1991; 11: 166-74
117. Beasley CM, Sayler ME, Weiss AM, et al. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992; 12: 328-33
118. Mander A, McCausland M, Workman B, et al. Fluoxetine induced dyskinesia. Aust NZ J Psychiatry 1994; 28: 328-30
119. Meghji C. Acquired stuttering [letler]. J Fam Pract 1994; 39: 325-6
120. Coulter DM, Pillians PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152: 122-5
121. Haenel T, Stockli HR, Truog P. A case of rare side effects of certain antidepressant drugs. Nervenartz 1995; 66: 70-2
122. Betschy G, Vandel S. Fluoxetine related indifference and akathisia: a case report. Therapie 1993; 48: 158-9
123. Ruiz F. Fluoxetine and the serotonin syndrome. Ann Emerg Med 1994; 24: 983-5
124. Singh RK, Gupta AK, Singh B. Acute organic brain syndrome after fluoxetine treatment. Am J Psychiatry 1995; 152: 295-6
125. Hoehn-Saric R, Lipsey JR, McLeod DR. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990; 10: 343-5
126. Mirow S. Cognitive dysfunction associated with fluoxetine [letter]. Am J Psychiatry 1991; 148: 948-9
127. Mandalos GE, Szarek BL. Dose-related paranoid reaction associated with fluoxetine. J Nerv Ment Dis 1990; 178: 57-8
128. Grounds D, Stocky A, Evens P, et al. Antidepressants and side effects. Aust NZ J Psychiatry 1995; 29: 156-7
129. Bhavnani SM, Levin GM. Antipsychotic agents: a survey of the prevalence, severity and burden of side effects. Int Clin Psychopharmacol 1996; 11: 1-12
130. McClelland GR, Cooper SM, Pilgrim AJ. A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 1990; 30: 795-803
131. Hindmarch l. Instrumental assessment of psychomotor functions and the effects of psychotropic drugs. Acta Psychiatr Scand 1994; 89: s49-52
132. Wylie KR, Thompson DJ, Wildgust HJ. Effects of depot neuroleptics on driving performance in chronic schizophrenic patients. J Neurosurg Psychiatry 1993; 56: 910-3
133. King DJ. Measures of neuroleptic effects on cognition and psychomotor performance in healthy volunteers. In: Hindmarch l, Stonier PD, editors. Human Psychopharmacology. Vol 4. Chichester: John Wiley & Sons Ltd, 1993: 195-209
134. Quigley N, Morgan D, Idzikowski C, et al. The effect of chlorpromazine and benzhexol on memory and psychomotor function in healthy volunteers. J Psychopharmacol 1996; 10: 146-52
135. Liljequist R, Linnoila M, Mattila MJ, et al. Effects of two weeks' treatment with thioridazine, chlorpromazine, sulpiride, and bromazepam, alone or in combination with alcohol, on learning and memory in man. Psychopharmacologia 1975; 44: 205-8
136. Bartfai A, Wiesel FA. Effects of sulpiride on vigilance in healthy subjects. Int J Psychophysiol 1986; 4: 1-5
137. Fagan D, Scott DB, Mitchell M, et al. Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology 1991; 105: 225-9
138. Mattila MJ, Mattila ME, Konno K, et al. Objective and subjective effects of remoxipride, alone and in combination with ethanol or diazepam, on performance in healthy subjects. J Psychopharmacol 1988; 2: 138-49
139. Mattila MJ, Patat A, Seppällä T, et al. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. Eur J Clin Pharmacol 1996; 51: 161-6
140. King DJ, Best P, Lynch D, et al. The effects of remoxipride and chlorpheniramine on eye movements and psychomotor performance in healthy volunteers. J Psychopharmacol 1995; 9: 143-50
141. Rammsayer T, Gallhofer B. Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles. Int Clin Psychopharmcol 1995; 10: 31-7
142. Ramaekers JG, Louwerens JW, Muntjewerff ND, et al. Effects of single and repeated doses of amisulpride (50 and 400 mg/d) and haloperidol (4mg/d) on psychomotor, cognitive, extrapyramidal and affective functions in healthy young volunteers. Technical report. Maastricht: Institute for Human Psychopharmacology, 1996
143. Jackson DM, Ryan C, Evenden J, et al. Preclinical findings with new antipsychotic agents: what makes them atypical? Acta Psychiatr Scand 1994; 89: s41-8
144. Leysen JE, Gommeren W, Schotte A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In: Kane JM, Moller HJ, Wouters FA, editors. Serotonin in antipsychotic treatment. New York: Marcel Dekker, New York, 1996: 51-75
145. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotics: a critical analysis. Psychopharmacology 1996; 124: 2-34
146. Saletu H, Grünberger J, Linzmayer, et al. Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry. Pharmacopsychiatry 1987; 20: 12-27
147. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
148. Levander T. Neuroleptics and the neuroleptic induced deficit syndrome. Acta Psychiatr Scand 1994; 89: sS-13
149. King DJ. Psychomotor disturbances induced by neuroleptics. Acta Psychiatr Scand 1994; 889: s53-9
150. Lader M. Historical introduction. Proceedings of the first international meeting on the neuroleptic induced deficit syndrome. Acta Psychiatr Scand 1994; 89: s6-7
151. King DJ. Guidelines for the use of antipsychotic drugs studies in healthy volunteers. J Psychopharmacol 1997; 11: 201-9
152. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97
153. Perrault GH, Depoortere R, Morel E, et al. Amisulpride: an atypical antipsychotic with D2/D3 dopamine receptor antagonistic activity and limbic selectivity. II: behavioral profile. J Pharmacol Exp Ther 1997; 280: 73-82
154. Rombaut NEI, Hindmarch I. Psychometric aspects of antihistamines: a review. Hum Psychopharmacol 1994; 9: 157-69
155. Vuurman EFPM, Van Veggel LMA, Uiterwijk MMC, et al. Seasonal allergic rhinitis and antihistamine effects on childrens' learning. Ann Allergy 1993; 71: 121-6
156. Vuurman EFPM, Van Veggel LMA, Sanders RL, et al. Effects of semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Allerg Asthma Immunol 1996; 76: 247-52
157. Vermeeren A, O'Hanlon JF, Fidler C. A single centre, double-blind, placebo-controlled, cross-over study to compare the effects of four dosage regimens of fexofenadine hydrochloride on car driving and psychomotor performance. Technical report. Maastricht: Institute for Human Psychopharmacology, 1996
158. Stanley N, Alfort CA, Rombaut NEI, et al. Comparison of the effects of astemizole/pseudoephedrine and triprolidine/pseudoephedrine on CNS activity and psychomotor function. Int Clin Psychopharmacol 1996; 11: 31-6
159. Ramaekers JG, Van Leeuwen C, O'Hanlon JF. A comparison of the effects of chlorpheniramine 8 and 12mg, hs, when used with lerfenadine 60mg, qam, on volunteers' driving performance versus those of placebo, and flurazepam 30mg, hs. Technical report. Maastricht, Institute for Human Psychopharmacology, 1997
160. Roehrs T, Claiburue R, Knox M, et al. Effects of ethanol, diphenhydramine and triazolam after a nap. Neuropsychopharmacology 1993; 9: 239-45
161. Schwartz JC, Arrang JM, Garbarg M, et al. Histamine. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1994: 347-405
162. Patten SB, Love EJ. Drug-induced depression: incidence, avoidance and management. Drug Saf 1994; 10: 203-19
163. Gleiter CH, Deckert J. Adverse effects of beta-adrenoceptor blockers. Pharmacopsychiatry 1996; 29: 201-11
164. Carter GL, Dawson AH, Lopert R. Drug induced delirium. Incidence, management and prevention. Drug Saf 1996; 15: 291-301
165. Peet M, Peters S. Drug-induced mania. Drug Saf 1995; 12: 146-53
166. Beers MH, Ouslander JG, Rollinger l, et al. Explicit criteria for determining inappropriate medication use in nursing homes. Arch Intern Med 1991; 151: 1825-32
167. Wilcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community elderly. JAMA 1994; 272: 292-6
168. Lamy PP, Salzman C, Nevis-Olesen J. Drug prescribing patterns, risks, and compliance guidelines. In: Salzman C, editor. Clinical Geriatric Psychopharmacology. 2nd ed. Ballimore: Williams & Wilkins, 1992: 15-37
169. Larson EB, Kukull WA, Buchner D, et al. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169-73
170. Brøsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Pharmacol 1996; 11: 23-7
171. Lasher TA, Fleishaker JC, Steenwyck RC, et al. Pharmacokinetic, pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991; 104: 323-7
172. Kroboth PD, Folan MM, Lusch RM, et al. Coadministration of nefazodone and benzodiazepines. I: pharmacodynamic assessment. J Clin Pharmacol 1995; 15: 306-19
173. Lader M, Melhuish A, Freka G, et al. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 1986; 31: 183-90
174. Allen D, Lader M, Curran V. A comparative study of the interactions of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 63-80
175. Stille G, Herberg KW. Traffic safety in treatment with dosulepin. Fortschr Med 1989; 107: 75-78
176. van Boxtel MPJ. Physical health, vascular risk factors and age-related cognitive decline: studies into physical determinants of normal cognitive aging. Maastricht: Neuropsych Publishers, 1997
177. Heggmann K, Greenlee P, Johns RE. Medication reporting in the workplace. J Occup Med 1991; 33: 1131-6